Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.

Peptide hormones are secreted from endocrine cells and neurons and exert their actions through activation of G protein-coupled receptors to regulate a diverse number of physiological systems including control of energy homeostasis, gastrointestinal motility, neuroendocrine circuits, and hormone secretion. The glucagon-like peptides, GLP-1 and GLP-2 are prototype peptide hormones released from gut endocrine cells in response to nutrient ingestion that regulate not only energy absorption and disposal, but also cell proliferation and survival. GLP-1 expands islet mass by stimulating pancreatic beta-cell proliferation and induction of islet neogenesis. GLP-1 also promotes cell differentiation, from exocrine cells or immature islet progenitors, toward a more differentiated beta-cell phenotype. GLP-2 stimulates cell proliferation in the gastrointestinal mucosa, leading to expansion of the normal mucosal epithelium, or attenuation of intestinal injury in experimental models of intestinal disease. Both GLP-1 and GLP-2 exert antiapoptotic actions in vivo, resulting in preservation of beta-cell mass and gut epithelium, respectively. Furthermore, GLP-1 and GLP-2 promote direct resistance to apoptosis in cells expressing GLP-1 or GLP-2 receptors. Moreover, an increasing number of structurally related peptide hormones and neuropeptides exert cytoprotective effects through G protein-coupled receptor activation in diverse cell types. Hence, peptide hormones, as exemplified by GLP-1 and GLP-2, may prove to be useful adjunctive tools for enhancement of cell differentiation, tissue regeneration, and cytoprotection for the treatment of human disease.

[1]  Q. Li,et al.  Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. , 1998, The Journal of clinical investigation.

[2]  M. Schwartz,et al.  GLP-2α accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion , 2001 .

[3]  B. Yusta,et al.  The Glucagon-like Peptide-2 Receptor Mediates Direct Inhibition of Cellular Apoptosis via a cAMP-dependent Protein Kinase-independent Pathway* , 2000, The Journal of Biological Chemistry.

[4]  D. Drucker,et al.  Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. , 1997, The American journal of physiology.

[5]  D. Irwin Molecular evolution of proglucagon , 2001, Regulatory Peptides.

[6]  J. Habener,et al.  Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. , 2001, Diabetes.

[7]  Ana D. Lopez,et al.  Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. , 2002, The Journal of clinical endocrinology and metabolism.

[8]  S. Bonner-Weir,et al.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. , 2000, Diabetes.

[9]  B. Yusta,et al.  Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. , 2000, Gastroenterology.

[10]  R. Perfetti,et al.  Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. , 2002, Endocrinology.

[11]  P. Brubaker,et al.  Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice , 2002, Diabetologia.

[12]  D. Drucker,et al.  Induction of intestinal epithelial proliferation by glucagon-like peptide 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Pritchard,et al.  cAMP-dependent Protein Kinase and Ca2+Influx through L-type Voltage-gated Calcium Channels Mediate Raf-independent Activation of Extracellular Regulated Kinase in Response to Glucagon-like Peptide-1 in Pancreatic β-Cells* , 2002, The Journal of Biological Chemistry.

[14]  N. Bunnett,et al.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Prentki,et al.  Glucose and glucoincretin peptides synergize to induce c‐fos, c‐jun, junB, zif‐268, and nur‐77 gene expression in pancreatic β(INS‐1) cells , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  A. Johnson,et al.  Vasoactive intestinal peptide-mediated suppression of apoptosis in the ovary: potential mechanisms of action and evidence of a conserved antiatretogenic role through evolution. , 1995, Endocrinology.

[17]  B. Yusta,et al.  Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. , 1999, The American journal of physiology.

[18]  J. Holst,et al.  Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats , 2002, Regulatory Peptides.

[19]  J. Egan,et al.  Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. , 1999, Endocrinology.

[20]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[21]  G. Dawson,et al.  Cyclic AMP Protects Against Staurosporine and Wortmannin‐Induced Apoptosis and Opioid‐Enhanced Apoptosis in Both Embryonic and Immortalized (F‐11κ7) Neurons , 1998 .

[22]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[23]  J. Bockaert,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP-38) Protects Cerebellar Granule Neurons from Apoptosis by Activating the Mitogen-Activated Protein Kinase (MAP Kinase) Pathway , 1997, The Journal of Neuroscience.

[24]  P. Yang,et al.  Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse , 2000, Gut.

[25]  D. Drucker,et al.  Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. , 2003, Diabetes.

[26]  B. Szende,et al.  Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. J. Larsen,et al.  Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem , 1997, Neuroscience.

[28]  Sakae Tanaka,et al.  Bcl-2 Lies Downstream of Parathyroid Hormone–related Peptide in a Signaling Pathway That Regulates Chondrocyte Maturation during Skeletal Development , 1997, The Journal of cell biology.

[29]  W. Chance,et al.  Maintaining Gut Integrity During Parenteral Nutrition of Tumor-Bearing Rats: Effects of Glucagon-Like Peptide 2 , 2000, Nutrition and cancer.

[30]  D. Sawyer,et al.  Adrenergic regulation of myocardial apoptosis. , 2000, Cardiovascular research.

[31]  B Perkins,et al.  Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. , 2000, Diabetes.

[32]  Jie Zhou,et al.  Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. , 1999, Diabetes.

[33]  P. Forgez,et al.  Neurotensin counteracts apoptosis in breast cancer cells. , 2002, Biochemical and biophysical research communications.

[34]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[35]  D. Drucker,et al.  Biological determinants of intestinotrophic properties of GLP-2 in vivo. , 1997, The American journal of physiology.

[36]  O. Chepurny,et al.  cAMP‐regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+‐induced Ca2+ release in INS‐1 pancreatic β‐cells , 2001, The Journal of physiology.

[37]  J. Palazzo,et al.  Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. , 2000, Journal of pediatric surgery.

[38]  B. Yusta,et al.  Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. , 2001, Cancer research.

[39]  M. Schwartz,et al.  Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. , 2000, Journal of pediatric surgery.

[40]  S. Chun,et al.  Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival factor. , 1996, Endocrinology.

[41]  B. Thorens Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Pandol,et al.  Cholecystokinin Induces Caspase Activation and Mitochondrial Dysfunction in Pancreatic Acinar Cells , 2002, The Journal of Biological Chemistry.

[43]  M. Bjerknes,et al.  Modulation of specific intestinal epithelial progenitors by enteric neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  V. Korolev,et al.  Cyclic AMP and sympathetic neuronal programmed cell death , 1997, Neurochemistry International.

[45]  J. Holst,et al.  Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.

[46]  D. Drucker Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. , 2001, Current pharmaceutical design.

[47]  W. Chance,et al.  Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. , 1997, The American journal of physiology.

[48]  John R. Christiansen,et al.  GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans , 1989, Digestive Diseases and Sciences.

[49]  B. Yusta,et al.  Glucagon-like Peptide-2 Receptor Activation Engages Bad and Glycogen Synthase Kinase-3 in a Protein Kinase A-dependent Manner and Prevents Apoptosis following Inhibition of Phosphatidylinositol 3-Kinase* , 2002, The Journal of Biological Chemistry.

[50]  D. Drucker,et al.  Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Delgado,et al.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptides (PACAP27) and PACAP38) protect CD4+CD8+ thymocytes from glucocorticoid-induced apoptosis. , 1996, Blood.

[52]  M. Prentki,et al.  Protein Kinase Cζ Activation Mediates Glucagon-Like Peptide-1–Induced Pancreatic β-Cell Proliferation , 2001 .

[53]  R. Goodlad,et al.  Proglucagon-Derived Peptides in Intestinal Epithelial Proliferation , 2001, Digestive Diseases and Sciences.

[54]  M. Hussain,et al.  Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. , 2000, Diabetes.

[55]  B. Yusta,et al.  Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. , 1999, The American journal of physiology.

[56]  S. Grinstein,et al.  Identification of Glucagon-like Peptide-2 (GLP-2)-activated Signaling Pathways in Baby Hamster Kidney Fibroblasts Expressing the Rat GLP-2 Receptor* , 1999, The Journal of Biological Chemistry.

[57]  M. Namba,et al.  Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide , 1989, Diabetes.

[58]  G. Weir,et al.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.

[59]  M. Delgado,et al.  Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Expression of Fas Ligand in Activated T Lymphocytes by Regulating c-Myc, NF-κB, NF-AT, and Early Growth Factors 2/31 , 2001, The Journal of Immunology.

[60]  M. Mattson,et al.  Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4 , 2002, Journal of Pharmacology and Experimental Therapeutics.

[61]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[62]  D. Drucker,et al.  Minireview: the glucagon-like peptides. , 2001, Endocrinology.

[63]  D. Drucker,et al.  Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. , 1997, The American journal of physiology.

[64]  G. Filippatos,et al.  Regulation of apoptosis by vasoactive peptides. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[65]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[66]  C. Behl,et al.  Corticotropin-releasing Hormone- Mediated Neuroprotection against Oxidative Stress Is Associated with the Increased Release of Non- Amyloidogenic Amyloid ␤ Precursor Protein and with the Suppression of Nuclear Factor-␬b Employing Primary Neurons and Clonal Cells, We Demonstrate That Crh Has a Neurop , 2022 .

[67]  C. B. Srikant,et al.  Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. , 1996, Molecular endocrinology.

[68]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[69]  M. Shichiri,et al.  Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[70]  D. Drucker,et al.  Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[71]  J. Holst,et al.  GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[72]  D. Drucker Glucagon-like Peptide 2 , 1999, Trends in Endocrinology & Metabolism.

[73]  R. Goodman,et al.  Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[74]  R. Nissenson,et al.  Apoptosis mediated by activation of the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein (PTHrP). , 2000, Molecular endocrinology.

[75]  W. MacNaughton,et al.  GLP-2 augments the adaptive response to massive intestinal resection in rat , 1998 .

[76]  C. Deacon,et al.  The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. , 2002, American journal of physiology. Endocrinology and metabolism.

[77]  J. Holst,et al.  Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. , 2001, Gastroenterology.

[78]  C. Wright,et al.  Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. , 2001, Diabetes.

[79]  F. Stivala,et al.  Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. , 1996, Molecular pharmacology.

[80]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[81]  J. Holst,et al.  Pancreatic and intestinal processing of proglucagon in man , 1987, Diabetologia.

[82]  W. Fujimoto,et al.  Effects of Glucagonlike Peptide l-(7–36) on Release of Insulin, Glucagon, and Somatostatin by Rat Pancreatic Islet Cell Monolayer Cultures , 1989, Diabetes.

[83]  Jie Zhou,et al.  Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats. , 2000, Endocrinology.

[84]  M. Prentki,et al.  Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells , 1999, Diabetologia.

[85]  S. Srinivasan,et al.  Molecular mechanisms for the antiapoptotic action of gastrin. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[86]  D. Sigalet,et al.  Hormonal therapy for short bowel syndrome. , 2000, Journal of pediatric surgery.

[87]  D. Drucker,et al.  Gut adaptation and the glucagon-like peptides , 2002, Gut.

[88]  S. Glaser,et al.  Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of Ca2+-dependent protein kinase C-alpha. , 2001, Journal of hepatology.

[89]  T. Shibasaki,et al.  Critical Role of cAMP-GEFII·Rim2 Complex in Incretin-potentiated Insulin Secretion* , 2001, The Journal of Biological Chemistry.

[90]  L. Orci,et al.  Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. , 1986, The Journal of biological chemistry.

[91]  F. Lezoualc’h,et al.  Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic ß-precursor protein and with the suppression of nuclear factor κB. , 2000 .

[92]  A. Hardikar,et al.  Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin. , 2002, Endocrinology.

[93]  D. Drucker,et al.  Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV , 1997, Nature Biotechnology.

[94]  P. Gros,et al.  Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid. , 1984, Endocrinology.

[95]  D. Drucker,et al.  Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. , 1997, The American journal of physiology.

[96]  G. Bell,et al.  Hamster preproglucagon contains the sequence of glucagon and two related peptides , 1983, Nature.

[97]  Jie Zhou,et al.  Glucagon-Like Peptide-1 Regulates the Beta Cell Transcription Factor, PDX-1, in Insulinoma Cells. , 1999, Endocrinology.

[98]  K. Kurokawa,et al.  Inhibitory effect of thyrotropic hormone on apoptosis induced by actinomycin D in a functioning rat thyroid cell line. , 1999, Endocrine journal.

[99]  J. Permert,et al.  Cholecystokinin octapeptide induces both proliferation and apoptosis in the rat pancreas , 2001, Regulatory Peptides.

[100]  John W. Adams,et al.  G-proteins in growth and apoptosis: lessons from the heart , 2001, Oncogene.

[101]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[102]  D. Hörsch,et al.  Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. , 2002, The Journal of endocrinology.

[103]  R Bicknell,et al.  Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth , 2001, Oncogene.

[104]  D. Drucker,et al.  Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard* , 1997, The Journal of Biological Chemistry.

[105]  J. Habener,et al.  Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. , 2002, Endocrinology.

[106]  Yazhou Li,et al.  Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* , 2003, The Journal of Biological Chemistry.

[107]  B. Tyrberg,et al.  β-Cell Differentiation from a Human Pancreatic Cell Line in Vitro and in Vivo , 2001 .

[108]  D. Drucker,et al.  Glucagon and related peptides in fetal rat hypothalamus in vivo and in vitro. , 1990, Endocrinology.

[109]  J. Egan,et al.  Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. , 2000, Endocrinology.

[110]  A. Edvell,et al.  Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umeå +/?). , 1999, Endocrinology.

[111]  H. Sakuta,et al.  Calcitonin gene-related peptide enhances apoptosis of thymocytes , 1996, Journal of Neuroimmunology.

[112]  Hen-Li Chen,et al.  Parathyroid Hormone and Parathyroid Hormone-related Protein Exert Both Pro- and Anti-apoptotic Effects in Mesenchymal Cells* , 2002, The Journal of Biological Chemistry.

[113]  Y. Kato,et al.  Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. , 1999, Journal of pediatric surgery.

[114]  Jie Zhou,et al.  Exendin‐4 differentiation of a human pancreatic duct cell line into endocrine cells: Involvement of PDX‐1 and HNF3β transcription factors , 2002, Journal of cellular physiology.

[115]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[116]  C. Culmsee,et al.  Corticotropin-Releasing Hormone Protects Neurons against Insults Relevant to the Pathogenesis of Alzheimer's Disease , 2001, Neurobiology of Disease.

[117]  J. Loeffler,et al.  PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. , 1997, DNA and cell biology.

[118]  K. Dickman,et al.  Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide , 2000, Regulatory Peptides.

[119]  B. Portha,et al.  Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. , 2002, Diabetes.

[120]  C. B. Srikant,et al.  G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification. , 1998, Biochemical and biophysical research communications.